Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Hongyun Biotechnology

Request full access

Structure-based drug discovery for oncology and rare diseases

ChinaFounded 2018

About Hongyun Biotechnology

Nanjing Hongyun Biotechnology Co., Ltd. is a clinical-stage biopharmaceutical company founded in 2018. The company leverages a proprietary drug discovery platform centered on structural pharmacology, integrating advanced computational technologies like molecular dynamics, AI, and computational chemistry. This platform aims to overcome drug resistance and address targets with high unmet clinical needs, particularly in oncology and rare diseases. One of the founders, Professor Caihong Yun, previously served as a research scientist at the Dana-Farber Cancer Institute and has extensive experience in structural biology and precision drug design. The CEO is Dr. Maijing Liao.

The company's business model focuses on the research and development of innovative small-molecule drugs. Its core technology facilitates the design of precision therapeutics by understanding the dynamic structures of proteins at an atomic resolution. This approach is intended to significantly improve the efficiency and success rate of new drug development. The company has established R&D centers in Shanghai and Beijing to create a comprehensive system covering structural pharmacology, chemical synthesis, and biological evaluation.

Hongyun Biotechnology's primary product pipeline includes H002, a next-generation EGFR tyrosine kinase inhibitor (TKI). This drug candidate is designed to treat non-small-cell lung carcinoma (NSCLC), specifically targeting resistance to third-generation EGFR inhibitors, such as those with the C797S mutation. As of early 2023, H002 has entered Phase I/IIa clinical trials in both the United States and China. Another pipeline project targeting a novel pathway for breast cancer and other tumors has advanced to the preclinical candidate stage. The company's revenue is primarily generated through venture capital funding, having completed multiple rounds, including a Series B+ round of nearly ¥100 million RMB in May 2023.

Source: Dealroom company data

At a glance

Status
Operational
Employees
1
Open positions
None listed
Dealroom signal
17.3/100

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC May 2023 $14M $55M Sherpa Venture Partners · Shanghai Renjin Investment Management Center · Fanchuang Capital · Huayin Financial Investment ↗
SERIES B✓Equity / VC Jul 2021 $14M $55M Undisclosed —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Hongyun Biotechnology team growth

Hongyun Biotechnology's team grew 0% over the past year.

1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Hongyun Biotechnology in its local ecosystem

Live from Dealroom

The Hongyun Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • Sherpa Venture Partners
  • DaYou Capital
  • Shanghai Renjin Investment Management Center
  • Fanchuang Capital
  • Huayin Financial Investment
  • Hetang Venture Capital
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Hongyun Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Hongyun Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.